Press corner
Latest news
January 2012 - Patent granted in several other countries (South Africa, Hong Kong, Singapore, Russia)
October 2011 - Licensing-in campaign launched to complement the pain pipeline
September 2011 - New board appointed - Philippe du Mesnil is the new president of the board.
July 2011 - Bridge financing to support new strategic plan focussing on regulatory development
July 2010 - First Neorphys patent granted in Europe EP 208 19 44 (first filing October 2006)
August 2009 - Neorphys has relocated to a new facility with extended space.Neorphys closes its second financing round. A second financing round of 1.2 M€ has been achieved in 2009 with Soridec, CEA Valorisation, Fa Diese 2, Seillans and a number of independent business angels. It will be used to complete the regulatory preclinical development of NEO1509.
Neorphys closes its 1st seed financing round. A first financing round of 1.05 M€ has been achieved in 2007 and 2008 with Inserm Transfert Initiative, Soridec and CEA Valorisation. It will be used to pursue the development of NEO1509, the lead analgesic drug candidate for visceral pain, up to regulatory preclinical studies and to expand its pain pipeline in other pain areas.
New French patent filed on April 2007, extended on April 2008, covering a new series of novel melanocortine agonists designed, synthesized and validated in vitro to date by the Neorphys scientists (patent FR-07/54279).
Neorphys gets a grant from Oseo Anvar and a grant from Crealia - Neorphys has obtained a 210K€ grant to support its innovative projects from Oseo Anvar and the Languedoc Roussilllon Regional Council and a 38K€ grant from Crealia.
Neorphys gets a grant from Europe and the Languedoc-Roussillon region - Neorphys has obtained a financial support from the European Union (European Fund of Regional Development) and the Languedoc Roussillon Regional Counsil for its innovative research programs.
Press coverage
- Neorphys - IndustriePharma n° 29 – 09/2007
- Neorphys : une stratégie basée sur deux domaines thérapeutiques - Biofutur n° 279 - 07/2007
- Neorphys finalise sa levée d’amorçage - Info Veille Biotech n°103– 25/04/2007
- Neorphys amorce la pompe à financement - BioPharmaceutiques n° 19 – 12/04/2007
- Update from Neorphys - R&D Focus Drug News Volume 16 n° 41 – 08/10/2006
- Neorphys combat la douleur aiguë - Soridec Newsletter – Automne 2007
- Au bord de l'orgasme - Libération (Sandrine Cabut) - 08/07/2006
- Neorphys : Un brevet nommé désir - Biotech Info n° 308 (François Anger) - 12/04/2006
Press releases
Neorphys closes its 1st financing round. A
first financing round of 1.05 M€ has been achieved in 2007
with Inserm Transfert Initiative, Soridec and CEA Valorisation (VCs).
It will be used to pursue the development of the analgesic drug
candidate up to the start of regulatory preclinical studies and to make
possible an animal assay for Neorphys second therapeutic axis, female
sexual dysfunction.
Download press release - pdf (56kb)
Télécharger
le communiqué - pdf (49kb)
